RenovoRx highlights Phase III TIGeR-PaC sub-study showing 51% tumor-site gemcitabine extraction with TAMP delivery
RNXT•Trial timeline and next catalysts
Enrollment in TIGeR-PaC has closed, with trial completion expected in H1 2027.
Initial top-line results are expected in H2 2027, a key catalyst for the TAMP platform and RenovoCath commercialization strategy.
Phase III TIGeR-PaC sub-study findings
RenovoRx highlighted a peer-reviewed PK/PD sub-study from its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer.
- Results have already been presented via publication, pointing to more tumor-focused chemotherapy delivery with lower whole-body exposure versus standard IV dosing.
- Data also linked drug metabolism patterns to improved tumor-marker readings, supporting a potential signal of better tumor penetration.
